Healthcare Sector — Q2 FY26 Earnings Overview
4 companies reported. 4 bullish, 0 neutral, 0 bearish.
Company Results
| Company | Revenue | YoY | Margin | Sentiment |
|---|---|---|---|---|
| Sunpharma | ₹14,405 Cr | +8.6% | 31.3% | bullish medium |
| Cipla | ₹7,589 Cr | +8% | 25.0% | bullish high |
| Apollo Hospitals Enterprise | ₹6,304 Cr | +13% | — | bullish high |
| Apollo Hospitals Enterprise | ₹6,304 Cr | +13% | 15.0% | bullish high |
Key sector risks this quarter
Potential tariffs on patented drug imports into the US could impact Sun Pharma's innovative portfolio, though generics are expected to be excluded.
Cipla · highGeneric Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.
Apollo Hospitals Enterprise · mediumEBITDA losses from six new hospitals could be ~INR 150 crore in FY27, potentially dragging consolidated margins if ramp-up is slower than expected.
Apollo Hospitals Enterprise · mediumInsurance contracts are reset every two years; with some contracts up for renewal, pricing may not keep pace with inflation, impacting revenue per patient.
Sunpharma · mediumLenalidomide sales have dropped YoY and are expected to be minimal in the second half, impacting US generics revenue.